Recent studies suggest that the presence of a KRAS mutation may be insufficient for defining a clinically homogenous molecular group, as many KRAS mutant tumors lose reliance on K-Ras for survival. Identifying pathways that support K-Ras dependency may define clinically relevant KRAS subgroups and lead to the identification of new drug targets. We have analyzed a panel of 17 KRAS mutant lung cancer cell lines classified as K-Ras-dependent or -independent for co-dependency on protein kinase C δ (PKCδ). We show that functional dependency on K-Ras and PKCδ co-segregate, and that dependency correlates with a more epithelial-like phenotype. Furthermore, we show that the pro-apoptotic and pro-tumorigenic functions of PKCδ also segregate based on K-Ras dependency, as K-Ras-independent cells are more sensitive to topoisomerase inhibitors, and depletion of PKCδ in this subgroup suppresses apoptosis through increased activation of extracellular signal-regulated kinase (ERK). In contrast, K-Ras-dependent lung cancer cells are largely insensitive to topoisomerase inhibitors, and depletion of PKCδ can increase apoptosis and decrease activation of ERK in this subgroup. We have previously shown that nuclear translocation of PKCδ is necessary and sufficient for proapoptotic signaling. Our current studies show that K-Ras-dependent cells are refractive to PKCδ-driven apoptosis. Analysis of this subgroup showed increased PKCδ expression and an increase in the nuclear:cytoplasmic ratio of PKCδ. In addition, targeting PKCδ to the nucleus induces apoptosis in K-Ras-independent, but not K-Ras-dependent non-small-cell lung cancer (NSCLC) cells. Our studies provide tools for identification of the subset of patients with KRAS mutant tumors most amenable to targeting of the K-Ras pathway, and identify PKCδ as a potential target in this tumor population. These subgroups are likely to be of clinical relevance, as high PKCδ expression correlates with increased overall survival and a more epithelial tumor phenotype in patients with KRAS mutant lung adenocarcinomas.
INTRODUCTION
Oncogenic mutations in KRAS occur in about 25% of lung adenocarcinomas resulting in constitutive activation of survival pathways including MEK/extracellular signal-regulated kinase (ERK) and PI3K/Akt. 1 Recently, subgroups of KRAS mutant lung and pancreatic tumors have been defined that differ in their reliance on K-Ras for survival. 2,3 K-Ras-dependent tumors are fully reliant on K-Ras, while K-Ras-independent tumors have lost their addiction to K-Ras and presumably depend on alternative pathways for survival. 2, 3 Direct targeting of K-Ras has been largely ineffective, and indirect targeting of K-Ras effectors, such as RAF, MEK and PI3K, has yielded mixed results. 4, 5 A better understanding of the molecular co-dependencies that promote survival of K-Ras-dependent tumors is important if additional drug targets are to be identified. Previous studies have shown that some cancer cells with oncogenic K-Ras are dependent on PKCδ for survival through a mechanism that involves regulation of ERK and/ or Akt. [6] [7] [8] [9] This suggests that PKCδ could represent a key pathway influencing outcomes from K-Ras-directed therapy.
The PKC family of serine/threonine kinases contributes to numerous biological processes, including proliferation, survival and apoptosis. [10] [11] [12] Studies in PKCδ knock-out mice have confirmed a role for this kinase in cell death in response to irradiation and during mammary gland involution. 13, 14 Likewise, many in vitro studies show that non-transformed cells use PKCδ for apoptotic signaling. 12 The finding that apoptotic pathways are often disabled in cancer cells may underlie the somewhat paradoxical observation that PKCδ activation may drive proliferation and survival in many tumor cells, and in in vivo tumor models. In mouse mammary gland cancer, PKCδ is a tumor promoter, and increased PKCδ expression is a negative prognostic indicator in Her+ and other subtypes of human breast cancer. 15 PKCδ also promotes tumor progression in human pancreatic and lung cancer. 9, 16 Other studies have defined roles for PKCδ in the invasion and migration of tumor cells, 17, 18 the regulation of integrin expression, proliferation downstream of the epidermal growth factor receptor 8, 19, 20 and endocytic recycling of growth factor receptors. [21] [22] [23] Here we show that the pro-apoptotic and pro-tumorigenic functions of PKCδ segregate based on K-Ras dependency, and define parameters for identification of subgroups of KRAS mutant tumors. Importantly, in patients with lung adenocarcinoma, high PKCδ expression correlates with a better prognosis, underscoring the clinical importance of our findings. Our studies may have implications for the selection of patients with KRAS mutant tumors that are more or less likely to respond to targeting of the K-Ras pathway, and support investigation of PKCδ as a therapeutic target in this patient population.
RESULTS

K-Ras-dependent NSCLC cells require PKCδ for survival
Although many tumor cells with oncogenic KRAS mutations require K-Ras for survival (that is, are 'K-Ras-dependent'), a subset of KRAS mutant non-small-cell lung cancer (NSCLC) cell lines are able to proliferate in the absence of K-Ras (that is, are 'K-Rasindependent'). 2 We have previously shown that PKCδ is required for the transformed phenotype and in vivo tumor growth of K-Rasdependent NSCLC cells, and that PKCδ regulates ERK activation and integrin α V β 3 expression in K-Ras-dependent NSCLC cells. 8, 9 As PKCδ is also a well-established regulator of DNA damageinduced apoptosis, 12, 24, 25 a critical question is whether the protumorigenic and pro-apoptotic functions of PKCδ segregate with functional dependency on K-Ras. For these studies, we used a panel of 17 KRAS mutant lung cancer cell lines, which include 10 K-Ras-dependent cell lines (H1734, H23, H441, H358, H1573, H2122, SW 900, H727, HCC-44 and H2009) and 7 K-Rasindependent cell lines (H157, SW-1573, Calu-6, A549, H460, H1792, H1155) in which depletion of K-Ras has no effect on cell survival (Supplementary Figure 1 ). We first determined the contribution of PKCδ to the tumorigenic growth of KRAS mutant NSCLC cells by assaying anchorage-independent growth (AIG) in cells stably depleted of PKCδ by expression of shRNAs (δ193 or δ203) or a scrambled control shRNA (δscr). Depletion of PKCδ using δ193 was X 90% and X 50% for δ203 (see Supplementary  Figure 2 ). Depletion of PKCδ with either shRNA significantly reduced the ability of all 10 K-Ras-dependent cell lines to form colonies in soft agar (Figure 1a ). Of these, H358 cells were the most dependent on PKCδ (480% decrease in AIG), while H1734 cells were the least dependent. In contrast, depletion of PKCδ had no effect, or in some cases significantly increased AIG in K-Rasindependent cells (Figure 1b ). The relative change in AIG across our cell line panel is depicted graphically in Figure 1c with numbers o1 indicating a requirement for PKCδ for tumorigenic growth. Plotting K-Ras dependency for survival (see Supplementary Figure 1 ) versus PKCδ-dependent AIG ( Figure 1c ) reveals two distinct subgroups of NSCLC cells ( Figure 1d ) and clearly demonstrates that dependency on oncogenic K-Ras and PKCδ are highly correlated (Pearson coefficient, r = 0.83, P o0.00004).
To explore the relationship between K-Ras and PKCδ further, A549, H2009 and H441 cells were transiently depleted of K-Ras by expression of shRNA (Figure 1e , gray bars) or a scrambled control shRNA (Figure 1e , black bars) and PKCδ mRNA expression was assayed. Depletion of K-Ras had no effect on expression of PKCδ in any of the cell lines analyzed (Figure 1e , top left). Similarly, we have shown that PKCδ depletion has no effect on K-Ras activation in NSCLC cells. 9 We next asked whether PKCδ supports AIG in K-ras-dependent cells through a collateral mechanism independent of K-Ras. We have previously shown that PKCδ regulates AIG in K-Ras-dependent NSCLC cells through regulation of integrin α V and β 3 expression. 8 To determine if PKCδ regulation of α V and β 3 requires K-Ras, we assayed mRNA expression in H2009 and H441 cells after depletion of K-Ras. In contrast to depletion of PKCδ (Figure 1f ), depletion of K-Ras had no effect on integrin α V expression in K-Ras-dependent cells; however, integrin α V expression was reduced in K-Ras-depleted A549 cells (Figure 1e , bottom left). Integrin β 3 expression was more variable but followed a similar trend (Figure 1e , bottom right). Our data is consistent with a role for PKCδ in supporting AIG and survival signaling in K-Rasdependent cells through a mechanism that does not require K-Ras.
PKCδ drives apoptosis in K-Ras-independent, but not -dependent NSCLC cells Our studies identify PKCδ as a potential therapeutic target in lung cancer cells that are functionally dependent on K-Ras. However, many non-transformed cells require PKCδ for DNA damageinduced apoptosis, which is also important for the therapeutic response of tumor cells to genotoxins. 12, [24] [25] [26] To determine if the pro-apoptotic function and pro-tumorigenic properties of PKCδ are mutually exclusive, our cell panel was treated with chemotherapeutic agents and apoptosis was assayed using a DNA fragmentation assay. As shown in Figures 2a and b , the protumorigenic PKCδ phenotype of K-Ras-dependent cells is strongly associated with resistance to the topoisomerase inhibitors, etoposide and SN38. A similar, albeit less significant, trend is seen when cells were treated with carboplatin, a DNA alkylating agent ( Figure 2c ). The response among K-Ras-independent cells to DNA damaging agents was variable, although overall they were nearly four times more responsive to etoposide and twice as responsive to SN-38 as K-Ras-dependent cells (Figures 2a and b ). When cells were treated with the microtubule disruption agent, paclitaxel, some cell lines in both the K-Ras-dependent and -independent subgroups responded, with no significant difference in response between groups ( Figure 2d ).
Many tumor cells inactivate DNA damage-induced apoptotic pathways, suggesting a possible mechanism for the resistance of K-Ras-dependent cells to apoptosis. TP53, which encodes the tumor suppressor protein p53, is mutated in about 50% of NSCLC, and mutation of TP53 predicts resistance to chemotherapeutic drugs in lung and other types of cancer. 27 Analysis of TP53 mutations through the COSMIC (http://cancer.sanger.ac.uk/ cosmic) and UMD TP53 mutation databases (http://p53.fr) indicates that 4/7 K-Ras-independent cell lines have mutant TP53 (H157, H1792, H1155 and CaLu-6), while all 10 K-Rasdependent cell lines have TP53 mutations. 28 Specific TP53 mutations are summarized in Supplementary Table 1 . As not all TP53 mutations are inactivating, we verified the functional status of p53 by analyzing p53 stability, Ser15 phosphorylation and expression of the p53 target gene, p21. In a few cell lines with mutant TP53 (see H2009 and H727, Figure 2e ), treatment with etoposide increased p53 protein stability and/or Ser15 phosphorylation, as well as p21 expression, indicating a partially functional p53 protein. Notably, H2009 and H727 cells are among the least PKCδ dependent of the K-Ras-dependent NSCLC cells (see Figure 1c ). Of the K-Ras-independent cell lines, those with WT TP53 (A549, H460 and SW-1573) are among the most sensitive to etoposide, however, some K-Ras-independent cells with mutant TP53, particularly H157 cells, still showed sensitivity. Thus, while mutations in TP53 correlate with resistance to apoptosis and with a pro-tumorigenic function for PKCδ in K-Rasdependent cells, in the K-Ras-independent subgroup, wild-type TP53 alone does not predict sensitivity to apoptosis.
Our data suggest that the pro-apoptotic function of PKCδ, especially in the context of topoisomerase inhibitors, is lost or suppressed in K-Ras-dependent NSCLC cells, relative to K-Rasindependent cells. To explore this directly, we analyzed etoposideinduced apoptosis in cells depleted of PKCδ. Depletion of PKCδ with either δ193 or δ203 resulted in suppression of apoptosis in K-Ras-independent A549 and H460 cells compared to cells expressing δscr ( Figure 3a ). In contrast, depletion of PKCδ had little effect on etoposide-induced apoptosis, or synergized with etoposide to further increase DNA fragmentation in K-Rasdependent H2009 and HCC-44 cells (Figure 3c ).
We next explored the hypothesis that PKCδ is differentially linked to survival or apoptotic pathways in K-Ras-dependent and -independent NSCLC cells. We found no consistent differences in basal ERK or Akt activation between these NSCLC subsets (data not shown). However, our previous studies suggested that ERK activation is differentially regulated by PKCδ depletion in K-Rasdependent versus -independent NSCLC cells. 9 In our present study, we explored this further using our panel of cell lines. Our results show that basal ERK activation either increases, or does not change with depletion of PKCδ in the 7 K-Ras-independent NSCLC cell lines ( Supplementary Figure 2A) . In contrast, depletion of PKCδ suppresses basal ERK activation in 9/10 K-Ras-dependent NSCLC cell lines (Supplementary Figure 2B) . Interestingly, ERK activation in response to EGF stimulation did not differ in PKCδ-depleted A549 (K-Ras-independent) or H2009 (K-Ras-dependent) cells (Supplementary Figure 2C ), suggesting that PKCδ does not regulate epidermal growth factor receptor activation, and consistent with a role for PKCδ in regulating AIG and survival signaling through a mechanism that does not require K-Ras.
As ERK can be activated by DNA damage agents in some cells, and is thought to provide a survival signal, 29 we asked if differential basal activation of ERK could account for the different apoptotic phenotypes we observe upon depletion of PKCδ. Activation of ERK and its downstream kinase, pRSK90, was assayed in etoposide-treated A549 (K-Ras-independent) and H2009 (K-Rasdependent) cells depleted of PKCδ with siRNA ( Figures 3b and d) . In A549 cells, treatment with etoposide transiently increased activation of ERK and RSK90, and this was more robust when A549 cells are depleted of PKCδ (siNT versus siPKCδ, Figure 3b ). In contrast, in H2009 cells expressing siPKCδ, basal and etoposide induced pERK and pRSK90 were greatly reduced compared to siNT ( Figure 3d ). As increased ERK and RSK90 activation correlate with decreased apoptosis in A549 cells depleted of PKCδ, we hypothesized that activation of the ERK pathway may contribute to the suppression of apoptosis observed (see Figure 3a ). To test this, A549 cells depleted of PKCδ by stable expression of δ193 ( Figure 3e ) or by transfection of siPKCδ (Figure 3f ), were pretreated with the MEK inhibitor, PD98059, prior to the addition of etoposide. Pretreatment with PD98059 resulted in a nearly complete rescue of the apoptotic response in both δ193 ( Figure 3e ) and siPKCδ A549 cells ( Figure 3f ). We conclude that PKCδ is a negative regulator of basal ERK activity in K-Rasindependent cells, and that increased activation of ERK in A549 cells depleted of PKCδ (Figure 3b ) contributes to the suppression of apoptosis observed (Figure 3a ). In contrast, in K-Ras-dependent NSCLC cells, our data indicate that PKCδ is a positive regulator of ERK, as basal ERK activation is reduced with depletion of PKCδ ( Supplementary Figure 2 and Figure 3d ). K-Ras-dependent NSCLC cells are refractory to PKCδ-driven apoptosis As a group, K-Ras-dependent NSCLC cells are largely resistant to DNA damage-induced apoptosis, especially cell death induced by topoisomerase inhibitors (Figure 2 ). We have previously shown that apoptosis induced by topoisomerase inhibitors and irradiation requires nuclear import of PKCδ, and that a nuclear targeted form of PKCδ is a potent inducer of apoptosis. [30] [31] [32] [33] Thus, a possible explanation for the resistance of K-Ras-dependent NSCLC cells to apoptosis from topoisomerase inhibitors in our models could be impairment of PKCδ-activated apoptotic signaling. To address this, NSCLC cells were transduced with an adenovirus that expresses an SV40-NLS tagged PKCδ (Ad-δNLS) or an Ad-GFP control adenovirus. This form of PKCδ is constitutively active and targeted to the nucleus 30, 34 (inset, Figure 4a ). Expression of Ad-δNLS-induced apoptosis in K-Ras-independent A549 cells, but not in H441 or H358 K-Ras-dependent cells (Figure 4a ). Similarly, expression of Ad-δNLS was unable to sensitize K-Ras-dependent cells H358 and H441 to etoposide-induced apoptosis (Figure 4b ).
These data demonstrate that K-Ras-dependent NSCLC cells are refractory to apoptosis induced by nuclear-targeted PKCδ, and suggest that nuclear localization of PKCδ may be impaired or that nuclear localization and induction of apoptosis may be uncoupled in K-Ras-dependent cells. To explore this further, we assayed PKCδ expression and nuclear localization across our NSCLC cell line panel. Surprisingly, PKCδ mRNA ( Figure 4c ) and protein expression ( Figure 4d ) are both significantly increased in K-Ras-dependent cells as compared to K-Ras-independent cells. Likewise, the ratio of nuclear to cytoplasmic PKCδ was significantly higher in K-Rasdependent cells compared to -independent cells (Figure 4e ). Our studies suggest that K-Ras-dependent NSCLC cells are able to accumulate large amounts of nuclear PKCδ without inducing apoptosis, supporting our finding that nuclear targeting of PKCδ occurs but does not drive apoptosis in this cell population (Figures 4a and b) . Taken together, our data suggest that PKCδ provides an essential pro-survival signal in NSCLC cells dependent on K-Ras; however, PKCδ is no longer able to regulate DNA damage-induced apoptosis in this cell population. Furthermore, our studies identify high PKCδ expression and an increased PKCδ nuclear:cytoplasmic ratio as potential biomarkers for identification of K-Ras-dependent NSCLC cancers.
High PKCδ expression correlates with markers of epithelial differentiation and predicts increased patient survival In lung, colon and pancreatic cancer cells, K-Ras dependency correlates with an epithelial phenotype. 2, 3 As our studies link high PKCδ expression to K-Ras dependency, we asked if PKCδ dependency and/or expression correlates with a more epitheliallike phenotype in KRAS mutant NSCLC as indicated by increased expression of E-cadherin (CDH1) and decreased expression of vimentin (VIM). Analysis of publically available microarray data shows that the ratio of CDH1 mRNA to VIM mRNA is higher in all PKCδ-dependent cell lines compared to PKCδ-independent cell lines (r = 0.73; Figure 5a ), and nearly identical to the correlation between K-Ras dependency and CDH1/VIM mRNA (r = 0.78) in this NSCLC cell line panel. Likewise, we show that high PKCδ expression correlates with an increased ratio of CDH1/VIM mRNA in human lung adenocarcinomas, indicating a more epithelial phenotype in this tumor population ( Figure 5b ). PKCδ does not regulate E-cadherin or vimentin protein expression in NSCLC cells as there is no change in expression of either protein in K-Rasindependent or K-Ras-dependent NSCLC cells depleted of PKCδ ( Supplementary Figure 3) . Our studies suggest that PKCδ expression could potentially be a biomarker for identification of K-Ras-dependent NSCLC tumors. To address this, we asked if PKCδ mRNA expression can be used to identify clinically significant subpopulations of patients with lung adenocarcinomas. Tumors in the The Cancer Genome Atlas (TCGA) database were binned into PKCδ high and PKCδ low expressers, and further into those with KRAS mutations. High PKCδ expression was found to be a predictor of increased overall survival in KRAS mutant adenocarcinomas (Figure 5c ). We propose that high PKCδ expression is a marker of K-Ras dependence in KRAS mutant tumors, and that together with PKCδ nuclear: cytoplasmic ratio, may be useful for identifying patients most likely to benefit from K-Ras and/or PKCδ-directed therapy.
Interestingly, high PKCδ expression also predicted better overall survival when all lung adenocarcinomas were analyzed (Figure 5d ), suggesting that PKCδ may cooperate with additional oncogenic drivers in lung tumors.
DISCUSSION
Oncogenic mutation of KRAS is commonly observed in NSCLC, however, attempts at direct or indirect targeting of the KRAS oncogene itself have, to date, failed to generate any K-Ras-specific clinical therapies. 4, 35 Beyond the issues associated with the druggability of K-Ras itself, it is also likely that the presence of a KRAS mutation may be insufficient for defining a clinically homogenous molecular grouping. Based on prior in vitro data, K-Ras dependency versus independency represents an obvious additional filter that might need to be employed to direct K-Rasspecific therapies toward clinically relevant KRAS molecular subgroups. 2, 3 Here we show that continued reliance on K-Ras for survival (K-Ras 'addiction') is highly correlated with dependency on PKCδ. We propose that PKCδ represents a secondary, nononcogene co-addiction in tumor cells that are also addicted to oncogenic K-Ras. In K-Ras-dependent cells, TP53 appears to be uniformly mutant, CDH1:VIM ratios suggest an epithelial phenotype, PKCδ expression levels are increased with an increased nuclear:cytoplasmic ratio and basal ERK signaling is PKCδ dependent. This spectrum of changes results in reduced sensitivity to key cytotoxic agents, most notably topoisomerase inhibitors. Our findings support further exploration of PKCδ as a drug target in this patient population, and suggest that dependency on PKCδ may define the subset of KRAS mutant tumors most amenable to targeting of the K-Ras pathway and/or suitable for specific cytotoxic therapy.
The development of targeted therapies for cancer has exploited the finding that many tumor cells are reliant on the function of a specific activated oncogene for survival ('oncogene addiction'). 36 However, cancer cells can also become dependent on proteins that are non-essential for the survival of normal cells, a condition referred to as 'non-oncogene addiction'. 37 Identification of such functionally important pathways is critical for new target identification, and may enable the development of drugs with greater tumor specificity. Such pathways may also provide additional opportunities for simultaneous targeting if they provide collateral support for oncogenic signaling. We have previously shown that depletion of PKCδ does not suppress K-Ras activation in K-Ras-dependent NSCLC cells; however, these studies did not address a role for K-Ras in regulation of PKCδ. 9 Here we show that depletion of K-Ras has no effect on the expression of PKCδ in any of the NSCLC cell lines analyzed (Figure 1e) , supporting a function for PKCδ independent of K-Ras. Our previous studies also identified the integrin pair α V β 3 as a downstream target of PKCδ specifically in K-Ras-dependent NSCLC cells, and showed that PKCδ regulation of integrin α V β 3 is required for AIG. 8 Here we show that while α V and β 3 expression in K-Ras-dependent NSCLC cells require PKCδ, it does not require K-Ras (Figure 1e ). We conclude that even though dependency on K-Ras and PKCδ cosegregate in K-Ras-dependent NSCLC cells, PKCδ likely supports 39 We propose that the reliance of K-Ras-dependent NSCLC cells on PKCδ for survival represents a non-oncogene addiction. This is consistent with the observation that PKCδ is a tumor promoter in vivo, but that functional genetic alterations in PKCδ are only rarely found in human cancers. 11, 40 However, changes in PKCδ expression have been reported in some human tumors 41, 42 and analysis of TCGA data shows increased expression of PKCδ in a subgroup of lung adenocarcinomas. 43 A future goal will be to use PKCδ expression/localization, possibly in combination with other genetic markers of K-Ras dependency, to classify patient's tumors by K-Ras-dependent and -independent status. As our studies suggest that PKCδ functions in a collateral pathway to support oncogenic K-Ras-driven tumorigenesis, co-targeting of K-Ras and PKCδ may likewise be an important strategy in K-Ras-dependent tumors. Notably, changes in PKCδ expression in lung adenocarcinomas are co-occurrent (odds ratio 42 and o10) with K-Ras activation (P o 0.008; www.cbioportal.org), supporting a link between these signaling pathways.
Our current data show that lung cancer cells addicted to oncogenic K-Ras are co-dependent on PKCδ for maintenance of basal ERK signaling, as PKCδ is required for basal activation of ERK specifically in this subgroup of cells ( Supplementary Figure 2  panels A and B) . Similarly, McCormick and colleagues 44 have shown that oncogenic K-Ras, but not wild-type K-Ras, regulates basal ERK signaling in KRAS mutant cancer cells. An interesting observation is that in our studies PKCδ does not regulate epidermal growth factor-induced ERK activation in either K-Ras subgroup (Supplementary Figure 2C) . As a non-oncogene addiction pathway, PKCδ may regulate survival pathways independent of K-Ras that impinge on ERK activation. For example, we have shown that PKCδ regulation of the integrin pair, α V β 3 , mediates ERK activation in K-Ras-dependent NSCLC cells. 8 PKCδ can also suppress ERK activation via negative regulation of hedgehog signaling, 45 and contributes to ERK activation through regulation of recycling of activated cell surface receptors as has been shown for ErbB2, KIT and epidermal growth factor receptor. 21, 23 Other studies by Xia et al. 6, 7 show that PKCδ is required for survival of NIH3T3 and pancreatic cancer cells expressing activated K-Ras through a mechanism resulting in activation of Akt.
In contrast to the strong correlation between K-Ras dependency and a pro-survival role for PKCδ, K-Ras-independent NSCLC cells are much more sensitive to DNA damaging agents, particularly the topoisomerase inhibitors etoposide and SN38. Hence K-Rasindependent NSCLC cells appear to be similar to nontransformed cells in their utilization of PKCδ for apoptosis. 12 In contrast, K-Ras-dependent NSCLC cells are highly refractory to pro-apoptotic signaling by PKCδ. The identification of subgroups of KRAS mutant cells with distinct PKCδ functions may explain previous reports that PKCδ can be either pro-or anti-apoptotic in cancer cells with aberrant K-Ras activation. 6, 46 We show that resistance of K-Ras-dependent NSCLC cells to DNA damageinduced apoptosis is not due to impaired nuclear localization or reduced expression/activation of PKCδ. In fact, K-Ras-dependent NSCLC cells have higher PKCδ expression and increased basal nuclear localization of PKCδ, suggesting that nuclear localization of PKCδ and apoptotic signaling are dissociated in this subgroup. Furthermore, our studies suggest that high nuclear PKCδ may be an indicator of apoptotic resistance. One mechanism for apoptosis resistance may be genetic inactivation of DNA damage response or apoptosis pathways. In this regard, all K-Ras-dependent cells have point mutations in TP53, while TP53 mutations occur in only 4/7 K-Ras-independent cell lines. Interrogation of the COSMIC database also shows increased mutation/copy number alterations in the damage sensors ATM/ATR in K-Ras-dependent cells (7/10) compared to K-Ras-independent cells (2/6), and mutations in caspases 7, 8 and 10 in 3/10 of the K-Ras-dependent cell lines, but not in K-Ras-independent cells (http://cancer.sanger.ac.uk/cosmic). Finally, our studies suggest that the ERK pathway is important for determining sensitivity to apoptosis as pretreatment with MEK inhibitors increases etoposide-induced apoptosis in K-Ras-independent NSCLC cells (Figures 3e and f) .
Our studies show that K-Ras dependency is highly correlated with dependency on PKCδ in a subgroup of KRAS mutant NSCLC cells, supporting exploration of PKCδ as a drug target in KRAS mutant lung cancer. Other studies have demonstrated a synthetic lethal interaction between K-Ras and PKCδ, 47 and a recent report shows that activation of PKCδ confers resistance to ALK inhibitors in ALK-dependent NSCLC cells. 48 The plasticity of PKCδ signaling in lung cancer cells illustrates the need to better understand the genetic context of specific cancer subtypes so as to more accurately deploy targeted therapies. Interestingly, analysis of specific KRAS codon mutations shows that mutation of codon 61, which occurs in o 1% of lung cancers, is frequently found in K-Ras-independent NSCLC cells (3/7 cell lines), but not in K-Rasdependent NSCLC cell lines (0/10; http://cancer.sanger.ac.uk/ cosmic). 49 In patients with lung adenocarcinomas, and specifically in KRAS mutant lung adenocarcinomas, we show that high PKCδ expression is predictor of increased overall survival, and of a more epithelial phenotype. In addition, our studies suggest that K-Rasdependent lung cancers can further be distinguished by increased PKCδ expression and nuclear localization, resistance to DNA damage-induced apoptosis, and PKCδ-dependent activation of ERK signaling pathways. Hence, our current studies provide parameters for selection of patients most likely to benefit from targeting the K-Ras pathway and/or from specific cytotoxic drugs and provide support for development of PKCδ-directed therapies for use in this patient population.
MATERIALS AND METHODS
Cell culture NSCLC cell lines, A549, NCI-H460, Calu-6, H1155, SW1-573, NCI-H157, H1792, H1734, NCI-H2009, NCI-H727, SW 900, HCC-44, H1573, NCI-H441, H2122, H23 and NCI-H358, were acquired from the University of Colorado Denver lung SPORE cell bank. Cell line profiling for authentication was done at the DNA sequencing Core at University of Colorado Anschutz Medical Campus using the AmpFLSTR Identifiler PCR Amplification Kit from Applied Biosystems (Foster City, CA, USA). Cells were maintained in RPMI-1640 with 2 mM L-glutamine and 10% fetal bovine serum. See Supplementary Table 1 for the histology, KRAS and TP53 mutational status of the cell panel.
siRNA and shRNA Transient depletion of PKCδ by siRNA was done using ON-TARGETplus SMARTpool siRNA for human PKCδ (L-003524-00-0010, Dharmacon, Thermo Fisher, Lafayette, CO, USA), and the ON-TARGETplus non-targeting Pool (D-001810-10-05). Stable depletion of PKCδ was performed as previously described using lentiviral constructs containing shRNA to human PKCδ (Open Biosystems, pLKO-TRC00010193 or pLKO-TRC00010203) or an shRNA control (pLKO-scrambled). 9 Cell lines were maintained in selection media with 1 μg/ml puromycin and used at low passage ( o8). Stable and transient depletion of K-Ras was performed using lentiviral constructs as previously described. 9, 50 Cell proliferation was assayed using WST-1 reagent (Sigma, St Louis, MO, USA).
Adenoviral transduction
Cells were plated at 2.5 × 10 3 cells per well of a 96-well plate. The following day cells were transduced with either Ad-GFP control or an SV40-NLS and GFP-tagged PKCδ (Ad-δNLS) at amultiplicity of infection of 100 and incubated with virus for 72 or 48 h with the addition of 50 μM etoposide for the last 24 h. 30 Nuclear localization of δNLS was verified by fluorescent microscopy using an Olympus BX51 microscope and a × 100 oil immersion objective.
Immunoblot analysis
Immunoblot analysis was done as previously described. 14 Antibodies to PKCδ (sc-937) and lamin B (sc-6217) were purchased from Santa Cruz Biotech (Santa Cruz, CA, USA); antibodies to phospho-ERK1/2 (pERK1/2; #9101), ERK1/2 (#4695), P-P53 (#9284), p53 (#2524), p21 (#2946) and vimentin (#5741) were purchased from Cell Signaling Technologies (Danvers, MA, USA). Antibodies to pRSK90 (#AF889) and RSK90 (#AF992) were obtained from R&D Systems (Minneapolis, MN, USA). The antibody to β-actin (ab49900) was purchased from Abcam (Cambridge, MA, USA). Antibodies to β-tubulin (556321) and e-cadherin (610182) were obtained from BD Biosciences (San Jose, CA, USA). For some experiments, nuclear and cytosol fractions were isolated using a nuclear/cytosol fractionation kit (BioVision Incorporated, Milpitas, CA, USA; # K266-100) according to the manufacturer's instructions, except that Triton X-100 was added to the nuclear extraction buffer at a final concentration of 1%. Protein concentration was determined using the DC Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA, USA; # 500-0111).
Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA was purified from NSCLC cells using a Zymo Research Quick RNA miniprep kit (Irvine, CA, USA; R1055) and 125 ng was reverse transcribed using Thermo Verso cDNA kit (Thermo Fisher, Waltham, MA, USA; AB1453). Biological triplicates of cDNA for each cell line were analyzed by PCR using Taqman Universal Master Mix II with UNG (Applied Biosystems 4440038) and Taqman probes recognizing PRKCD (Hs01090047_m1) or RNA18s control (Hs03928990_g1). Analysis was performed using RNA18s as the endogenous control and A549 cDNA as the reference. Relative mRNA levels for ITGAV, ITGB3, PRKCD, KRAS and GAPDH were determined using the following primer sets and Applied Biosystems SYBR Select Master Mix (#4472897): ITGAV, forward 5′-AGGAGAAGGTGCCTACGAAGCT-3′, reverse 5′-GCACAGGAAAGTCTTGCTAAGGC-3′, ITGB3, forward 5′-AAGCAGAGTGT GTCACGGAACC-3′, reverse 5′-CCTCCAGCCAATCTTTTCATCAC-3′; PRKCD, 5′-CAGACCAAGGACCACCTGTT-3′, reverse 5′-GCATAAAACGTGGCACGGTA-3′; KRAS, forward 5′-ATTTTGTGGACGAATATGATCCAAC-3′, reverse 5′-GCTGTGT CGAGAATATCCAAGAGAC-3′ and GAPDH, forward 5′-GCCAAATATGATG ACATCAAGAAGG-3′, reverse, 5′-GGTGTCGCTGTTGAAGTCAGAG-3′. For these reactions, gene expression was normalized to GAPDH. All reactions were performed using the StepOnePlus Real-Time PCR system and a comparative C T (ΔΔC T ).
DNA fragmentation and AIG
DNA fragmentation was assayed using a Cell Death Detection ELISA PLUS (Sigma-Aldrich, St. Louis, MO, USA). AIG was assayed as described previously. 9 For each cell line, 1 × 10 4 cells were suspended in a top layer of 0.36% noble agar (USB Corporation, Cleveland, OH, USA) and a bottom layer of 0.4% agar both in RPMI-1640 + 10% FBS in a six-well culture dish. After 1-3 weeks, colonies were stained with Nitrotetrazolium Blue chloride (NBT; Sigma) and photographed with a S600 Canon camera. Colonies were quantified with ImageJ analysis software.
Analysis of TCGA data
RNA-seq gene expression and mutational data from lung adenocarcinoma patients was obtained from the TCGA through cBioPortal (https://www. cbioportal.org). Clinical data were obtained from the TCGA data portal (https://tcga-data.nci.nih.gov/tcga). In total, 230 patients that have matched clinical data and RNA-seq/mutational data were used in this analysis. Patients were classified into high or low PKCδ groups if the PKCδ expression of a patient was higher or lower than the mean expression. Kaplan-Meier survival analysis was conducted using PRISM software, and log-rank test Po0.05 was considered statistically significant.
